Clinical trial
Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung…
NCT00446225 · Spanish Lung Cancer Group, Other · Completed
Key facts
| NCT number | NCT00446225 |
|---|---|
| Title | Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR |
| Official title | Phase III, Multicenter, Open-label, Randomized Trial of Tarceva® vs Chemotherapy in Patients With Advanced NSCLC With Mutations in the TK Domain of the EGFR |
| Acronym | EURTAC |
| Lead sponsor | Spanish Lung Cancer Group, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Erlotinib, Carboplatin, Gemcitabin, Docetaxel, Cisplatin |
| Enrollment | 174 |
| Start date | Feb 15, 2007 |
| Primary completion | Apr 11, 2012 |
| Completion | Dec 1, 2012 |
| First posted | Mar 12, 2007 |
| Last update posted | Mar 5, 2025 |
| Countries | France, Italy, Spain |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: